HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL

URN to cite this document:: urn:nbn:de:bvb:355-epub-589680
DOI to cite this document:: 10.5283/epub.58968

Pathil, Anita ; Armeanu, Sorin ; Venturelli, Sascha ; Mascagni, Paolo ; Weiss, Thomas S.

; Gregor, Michael ; Lauer, Ulrich M. ; Bitzer, Michael

License: Creative Commons Attribution Non-commercial No Derivatives 4.0
PDF - Published Version
(814kB)

Date of publication of this fulltext: 20 Aug 2024 11:37

Alternative links to fulltext:DOI DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Abstract Hepatocellular carcinoma (HCC) displays a striking resistance to chemotherapeutic drugs or innovative tumor cell apoptosis–inducing agents such as tumor necrosis factor–related apoptosis-inducing ligand (TRAIL). Recently, we found 2 histone deacetylase inhibitors (HDAC-I), valproic acid and ITF2357, exhibiting inherent therapeutic activity against HCC. In TRAIL-sensitive cancer cells, ...